itziar borbolla

[Charlie Lees @charlie_lees]

UEG Week 2026 was the busiest IBD meeting I can remember. Here is what I have covered so far, all in one place.

Eight posts. Long-acting antibodies, diet, obefazimod, VERDICT, STRIDE-III, perianal Crohn's and subcut risankizumab, plus a full Substack piece on what VERDICT and STRIDE-III mean for the clinic.

Next up is combination therapy. DUET, TARGET-CD, and what I actually do in clinic.

Links to every post below.

[itziar borbolla @itziar_borbolla]

@ATTMx

[itziar borbolla @itziar_borbolla]

Cada vez está peor el servicio de AT&T; tengo contratado el plan anual y el 80% del día la señal se ve así: sin servicio. Es inaceptable pagar por un servicio que no funciona.
@ATT

[itziar borbolla @itziar_borbolla]

Cada vez está peor el servicio de AT&T; tengo contratado el plan anual y el 80% del día la señal se ve así: sin servicio. Es inaceptable pagar por un servicio que no funciona.
@ATT

[itziar borbolla @itziar_borbolla]

@BGomezluna Por?

[Tauseef Ali MD, FACG AGAF FACP @ibdtweets]

Everyone is talking about TL1A in IBD. But should we be watching DR3 too?

Most emerging therapies are trying to neutralize the messenger, TL1A. A different strategy is emerging: block the DR3 receptor and prevent the message from being received.

Same pathway. Different strategy.

Could receptor blockade offer more durable pathway suppression? Could combinations take us further? And the biggest question for me: can targeting the TL1A–DR3 axis finally make a meaningful dent in fibrosis?

A quick look at the other side of the TL1A story. 🔬

#IBD #TL1A #CrohnsDisease #DrugDevelopment #IBDLibrary

https://t.co/HVFcA18zG5

[Beatriz Gros @Bealoquebea]

1/ A resident asked me how to interpret the two UC guselkumab trials

Same drug (IV/SC induction). Different trial designs, denominators & clinical meaning!

QUASAR = responder re-randomization
ASTRO = randomized treat-through

✅ key lesson: before comparing numbers, understand the design

[Yuri Gorelik @GorelikYuri]

🛑RCT @AGA_CGH mod-to-sev UC - 8wk induction of VEDO+UPA vs mono-VEDO (no placebo👏)

Endoscopic remission (tough goal) 37.5% vs 15.1%‼️

Clinical remission 67% vs 40%‼️

AEs▶️7.5% vs 7%

https://t.co/XKAObyNYwd

[Keith Siau @drkeithsiau]

You are replaceable at work, but you are NOT replaceable at home. A beautiful and poignant reflection that applies to all clinicians.

[Sociedad Española de Patología Digestiva (SEPD) @sepdigestiva]

🔬📚 Revisión “state of the art” en enfermedad inflamatoria intestinal (EII)
(BMJ, diciembre 2025)
Un repaso actualizado y práctico sobre los aspectos clave de la EII:

1️⃣ Fisiopatología y nuevas dianas terapéuticas
2️⃣ Manifestaciones extraintestinales
3️⃣ Manejo de la colitis ulcerosa aguda grave
4️⃣ Enfermedad de Crohn postquirúrgica

Imprescindible para estar al día en el abordaje integral de la EII.
https://t.co/GubtZcSu5Q

[itziar borbolla @itziar_borbolla]

@BGomezluna 😱😱😱

[The Bottom Line IBD @bottomlineibd]

Interesting to read about the results of the PREdiCCt study out today in @Gut_BMJ.

⭐️ Calpro results predict flares before symptoms appear
⭐️ In UC (but not Crohn's), higher meat intake doubles flare risk
⭐️ UPFs and alcohol not associated with flares

https://t.co/SyhQYxArZM

[itziar borbolla @itziar_borbolla]

@BGomezluna Hola amigo! Cómo estás?

[itziar borbolla @itziar_borbolla]

Envie el correo que me solicitaron y me contestó un correo automático diciendo que no hay espacio para recibir correos. De mal en peor.
@MetLifeMx

[itziar borbolla @itziar_borbolla]

Pésima gestión de @MetLifeMx para el registro de nuevos proveedores médicos. 4 meses perdidos en un proceso donde nadie ayuda ni resuelve. No recomiendo afiliarse con ellos; su falta de soporte afecta directamente al gremio médico. 👎🏥 #AtencionAlCliente #MetLifeMexico

[itziar borbolla @itziar_borbolla]

@MetLifeMx Mismo problema, nadie en los centros de atención ayudan. Solicitan enviar documentos e información a un correo que nunca responden. #pesimo #atencionalcliente

[Rome PsychoGastroenterology @RomeGastroPsych]

🧘‍♀️ Yoga shows real promise for IBS relief
Latest systematic review found yoga improved #IBS symptoms, anxiety, and quality of life with moderate–large effects (Cohen’s d 0.37–3.6) versus controls
➡️ Mind–body therapy targeting both gut and brain
🔓https://t.co/BajTFNzQAC

[Keith Siau @drkeithsiau]

How prokinetics work in the GI tract ⏩💡 #4KMedEd

📸: https://t.co/LIjiUn5s3r

[United European Gastroenterology @my_ueg]

📢 Acute severe ulcerative colitis (ASUC) is an emergency condition which requires fast and informed care. The first days after hospitalisation are therefore crucial 🏥

🔗 Learn more in our online course on ASUC on Gutflix: https://t.co/PSqcYNoHnb

[Octavio Gomez-Escudero @octavio_gomezmd]

Clinical practice recommendations on the use of neuromodulators in Gastro. @gastromx and @motilidad expert joint review @chemaremes @drprapul @coss_enriquemd @pepebandera1 @ASENEM_ @DraBarba @alcala_glez_LG @umfoodoc @ForegutSociety @RevistadeGastr1
https://t.co/SsdnNh5cm0